Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines

Valentina Cecchinato(Università della Svizzera italiana), Raffaella Chiaramonte(University of Milan), Paola Comi(University of Milan), Claudia Fazi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Andrea Basile(University of Milan), Bruno Brando(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Barbara Scarpati(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Eugenio Erba(Mario Negri Institute for Pharmacological Research)
Leukemia Research
November 14, 2007
10.1016/j.leukres.2007.09.008
Cited by 11

Related Papers

Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques
|Mucosal Immunology|2008|242
SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection
|Blood|2007|172
Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells
|Biochemical Pharmacology|2007|118
Senescence-Dependent Regulation of Type 1 Plasminogen Activator Inhibitor in Human Vascular Endothelial Cells
|Experimental Cell Research|1995|110
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma
|Leukemia|2019|109